Document is current
Any future updates will be listed below
-
Authors
Moog, Tatum M.
Smith, Alexander D.
Burgess, Katy W.
McCreary, Morgan
Okuda, Darin T. https://orcid.org/0000-0002-6499-1523
- License Information
-
More Information
Article History
Received: 27 February 2023
Revised: 4 April 2023
Accepted: 5 April 2023
First Online: 13 April 2023
Declarations
:
: D.T.O. received personal compensation for consulting and advisory services from Alexion, Biogen, Celgene/Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Janssen Pharmaceuticals, Novartis, Osmotica Pharmaceuticals, RVL Pharmaceuticals, Inc., TG Therapeutics, Viela Bio, Inc., and research support from Biogen and EMD Serono/Merck. D.T.O. has issued national and international patents along with pending patents related to this current work and other developed technologies and has received royalties for intellectual property licensed by The Board of Regents of The University of Texas System. T.M.M., A.D.S., K.W.B., and M.M. have no relevant financial or non-financial interests to disclose.
: The protocol was approved by the UTSW Institutional Review Board and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments and granted a waiver for consent.
